Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) affects about one-third of patients with IBS, which is observed in about 12% of people across five continents. The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition. Areas covered: This review addresses the pharmacological treatments for IBS-D under three categories: drugs for IBS-D (i.e., the 5-HT3 antagonist, alosetron); drugs approved for other indications that are used in IBS-D (e.g., opioid agonists; other 5-HT3 antagonists; serotonergic psychoactive agents; bile acid binders; 5-ASA compounds; probiotics and non-absorbable antibiotics); as well as development of drugs that are likely to impact the management of IBS-D in the future (e.g., drug absorbents; TPH1 inhibitors; mast cell stabilizers; centrally acting benzodiazepines). The final section addresses key findings: regulatory roadblocks; weaknesses in the current research in this field so far and opportunities to address unmet needs including restoration of normal intestinal barrier function or permeability, and suppression within the intestines of local immune activation that is thought to trigger abnormal motor, sensory and secretory functions in IBS-D. Expert opinion: While symptomatic treatment of diarrhea is effective, there is a need for new treatments for the IBS-D complex. Greater understanding of the mechanisms in IBS-D has led to promising approaches to develop more efficacious therapies.

Original languageEnglish (US)
Pages (from-to)1151-1160
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number9
DOIs
StatePublished - Jun 2013

Fingerprint

Irritable Bowel Syndrome
Diarrhea
Pharmacology
Serotonin 5-HT3 Receptor Antagonists
Pharmaceutical Preparations
Therapeutics
Serotonin Agents
Psychotropic Drugs
Probiotics
Expert Testimony
Patient Education
Bile Acids and Salts
Benzodiazepines
Mast Cells
Opioid Analgesics
Intestines
Permeability
Anti-Bacterial Agents
Research

Keywords

  • Diarrhea
  • Intestinal motor function
  • Irritable bowel syndrome
  • Pharmacological treatments

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. / Camilleri, Michael.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 9, 06.2013, p. 1151-1160.

Research output: Contribution to journalArticle

@article{ab9e63a28fc744d9ae0daa80204f9def,
title = "Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome",
abstract = "Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) affects about one-third of patients with IBS, which is observed in about 12{\%} of people across five continents. The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition. Areas covered: This review addresses the pharmacological treatments for IBS-D under three categories: drugs for IBS-D (i.e., the 5-HT3 antagonist, alosetron); drugs approved for other indications that are used in IBS-D (e.g., opioid agonists; other 5-HT3 antagonists; serotonergic psychoactive agents; bile acid binders; 5-ASA compounds; probiotics and non-absorbable antibiotics); as well as development of drugs that are likely to impact the management of IBS-D in the future (e.g., drug absorbents; TPH1 inhibitors; mast cell stabilizers; centrally acting benzodiazepines). The final section addresses key findings: regulatory roadblocks; weaknesses in the current research in this field so far and opportunities to address unmet needs including restoration of normal intestinal barrier function or permeability, and suppression within the intestines of local immune activation that is thought to trigger abnormal motor, sensory and secretory functions in IBS-D. Expert opinion: While symptomatic treatment of diarrhea is effective, there is a need for new treatments for the IBS-D complex. Greater understanding of the mechanisms in IBS-D has led to promising approaches to develop more efficacious therapies.",
keywords = "Diarrhea, Intestinal motor function, Irritable bowel syndrome, Pharmacological treatments",
author = "Michael Camilleri",
year = "2013",
month = "6",
doi = "10.1517/14656566.2013.794223",
language = "English (US)",
volume = "14",
pages = "1151--1160",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome

AU - Camilleri, Michael

PY - 2013/6

Y1 - 2013/6

N2 - Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) affects about one-third of patients with IBS, which is observed in about 12% of people across five continents. The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition. Areas covered: This review addresses the pharmacological treatments for IBS-D under three categories: drugs for IBS-D (i.e., the 5-HT3 antagonist, alosetron); drugs approved for other indications that are used in IBS-D (e.g., opioid agonists; other 5-HT3 antagonists; serotonergic psychoactive agents; bile acid binders; 5-ASA compounds; probiotics and non-absorbable antibiotics); as well as development of drugs that are likely to impact the management of IBS-D in the future (e.g., drug absorbents; TPH1 inhibitors; mast cell stabilizers; centrally acting benzodiazepines). The final section addresses key findings: regulatory roadblocks; weaknesses in the current research in this field so far and opportunities to address unmet needs including restoration of normal intestinal barrier function or permeability, and suppression within the intestines of local immune activation that is thought to trigger abnormal motor, sensory and secretory functions in IBS-D. Expert opinion: While symptomatic treatment of diarrhea is effective, there is a need for new treatments for the IBS-D complex. Greater understanding of the mechanisms in IBS-D has led to promising approaches to develop more efficacious therapies.

AB - Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) affects about one-third of patients with IBS, which is observed in about 12% of people across five continents. The ultimate goal in this field is to identify the underlying cause of symptoms in order to individualize education of the patient, and to provide optimal treatment of this highly prevalent condition. Areas covered: This review addresses the pharmacological treatments for IBS-D under three categories: drugs for IBS-D (i.e., the 5-HT3 antagonist, alosetron); drugs approved for other indications that are used in IBS-D (e.g., opioid agonists; other 5-HT3 antagonists; serotonergic psychoactive agents; bile acid binders; 5-ASA compounds; probiotics and non-absorbable antibiotics); as well as development of drugs that are likely to impact the management of IBS-D in the future (e.g., drug absorbents; TPH1 inhibitors; mast cell stabilizers; centrally acting benzodiazepines). The final section addresses key findings: regulatory roadblocks; weaknesses in the current research in this field so far and opportunities to address unmet needs including restoration of normal intestinal barrier function or permeability, and suppression within the intestines of local immune activation that is thought to trigger abnormal motor, sensory and secretory functions in IBS-D. Expert opinion: While symptomatic treatment of diarrhea is effective, there is a need for new treatments for the IBS-D complex. Greater understanding of the mechanisms in IBS-D has led to promising approaches to develop more efficacious therapies.

KW - Diarrhea

KW - Intestinal motor function

KW - Irritable bowel syndrome

KW - Pharmacological treatments

UR - http://www.scopus.com/inward/record.url?scp=84877911333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877911333&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.794223

DO - 10.1517/14656566.2013.794223

M3 - Article

C2 - 23621801

AN - SCOPUS:84877911333

VL - 14

SP - 1151

EP - 1160

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 9

ER -